A Study to Monitor the Health of Participants in HIVNET 014 Who Become Infected With HIV-1
Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001
Trial Information
Current as of May 18, 2025
Completed
Keywords
ClinConnect Summary
There are many possible outcomes of HIV-1 infection among persons who receive experimental HIV-1 vaccines. In the best-case scenario, these vaccines may prevent infection (sterilizing immunity). However, current viral vaccines are thought to limit, but not prevent, virus replication after infection. In the latter case, it is important to document the effect of the immune response on the disease course as reflected by viral load, the evolution of the viral quasi species, and clinical symptoms over time. Understanding the evolution of the immune response in vaccinees after subsequent exposure...
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- Patients may be eligible for this study if they:
- • Become infected with HIV while participating in HIVNET 014, or if they are an HIV-positive partner (sexual or needle-sharing) of a HIVNET 014A participant.
- • Are able and willing to provide written informed consent.
- • Exclusion Criteria
- Patients will not be eligible for this study if they:
- • Have a serious psychiatric or psychological disorder that would prevent them from completing the study.
About National Institute Of Allergy And Infectious Diseases (Niaid)
The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seattle, Washington, United States
Bronx, New York, United States
New York, New York, United States
Philadelphia, Pennsylvania, United States
Providence, Rhode Island, United States
Pawtucket, Rhode Island, United States
San Francisco, California, United States
Denver, Colorado, United States
Chicago, Illinois, United States
Boston, Massachusetts, United States
Chicago, Illinois, United States
Patients applied
Trial Officials
Connie Celum
Study Chair
Susan Buchbinder
Study Chair
Haynes Sheppard
Study Chair
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials